Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boost for Genomic Health as Oncotype DX makes ASCO (American Society of Clinical Oncology's) guidelines:

This article was originally published in Clinica

Executive Summary

Genomic Health's breast cancer prognostic - Oncotype Dx - has been included in the American Society of Clinical Oncology's (ASCO) updated guidelines. The move could spell a boost in sales for the product, which is used to determine the likelihood of disease recurrence and of chemotherapy benefit for node-negative, oestrogen receptor-positive patients. The guidelines will appear in the Journal of Clinical Oncology on November 20. The inclusion of Oncotype DX is based on multiple independent clinical studies involving over 2,600 patients, claimed the Redwood City, California firm. ASCO guidelines serve as a guide for doctors and outline appropriate methods for treatment and care.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel